Human herpesvirus-6 in hematopoietic stem cell transplant recipients: a prospective cohort study in Egypt

Table 1 Characteristics of allogeneic and autologous hematopoietic stem cell transplant recipients

	Allogeneic HSCT recipients (n = 12)		Autologous HSCT recipients (n = 28)
	No	%	No	%
Gender
Male	10	83.3	15	53.6
Female	2	16.7	13	46.4
Age (years)
Min.–Max	19.0–43.0		19.0–72.0
Mean ± SD	27.83 ± 7.36		45.89 ± 13.71
Median (IQR)	27.50 (22–32)		45.0 (38–56)
Source of stem cells
PBSCT	12	100.0	28	100.0
Underlying haematologic disease
AML	7	58.3	0	0.0
ALL	3	25.0	0	0.0
Biphenotypic acute leukemia	1	8.3	0	0.0
Aplastic anaemia	1	8.3	0	0.0
HL	0	0.0	7	25.0
NHL	0	0.0	4	14.3
Multiple Myeloma	0	0.0	17	60.7
HLA disparity
Matched related	12	100.0
Conditioning regimen
MAC
Busulfan + cyclophosphamide	11	91.7	0	0.0
RIC
Cylophosphamide + fludarabine	1	8.3	0	0.0
BEAM protocol	0	0.0	11	39.3
Melphalan	0	0.0	17	60.7
GVHD prophylaxis
Methotrexate + cyclosporine A	12	100.0
Anti-viral prophylaxis
Acyclovir	12	100.0	28	100.0
Seropositive (IgG)
HHV-6	11	91.7	23	82.1
CMV	12	100.0	26	92.9
EBV	12	100.0	25	89.3

HSCT hematopoietic stem cell transplant, PBSCT peripheral blood stem cell transplant, BMT bone marrow transplant, CBT cord blood transplant, AML acute myeloid leukemia, ALL acute lymphocytic leukemia, HL Hodgkin’s lymphoma, NHL non Hodgkin’s lymphoma, MAC myeloablative conditioning, RIC reduced intensity conditioning, GVHD graft versus host disease, HHV-6 human herpesvirus-6, CMV cytomegalovirus, EBV Epstein Barr virus

ISSN: 1743-422X